P2‐Quinazolinones and Bis‐Macrocycles as New Templates for Next‐Generation Hepatitis C Virus NS3/4a Protease Inhibitors: Discovery of MK‐2748 and MK‐6325
Citations Over TimeTop 12% of 2015 papers
Abstract
With the goal of identifying inhibitors of hepatitis C virus (HCV) NS3/4a protease that are potent against a wide range of genotypes and clinically relevant mutant viruses, several subseries of macrocycles were investigated based on observations made during the discovery of MK-5172. Quinazolinone-containing macrocycles were identified as promising leads, and optimization for superior cross-genotype and mutant enzyme potency as well as rat liver and plasma concentrations following oral dosing, led to the development of MK-2748. Additional investigation of a series of bis-macrocycles containing a fused 18- and 15-membered ring system were also optimized for the same properties, leading to the discovery of MK-6325. Both compounds display the broad genotype and mutant potency necessary for clinical development as next-generation HCV NS3/4a protease inhibitors.
Related Papers
- → West Nile Virus (WNV) protease and membrane interactions revealed by NMR spectroscopy(2012)8 cited
- Development of a cell-based assay for monitoring hepatitis C virus ns3/4a protease activity.(2008)
- → Identification of the protease domain in NS3 of hepatitis C virus(1995)38 cited
- → Generation of a Novel Poliovirus with a Requirement of Hepatitis C Virus Protease NS3 Activity(1996)31 cited
- Clinical application and analysis of hepatitis C virus NS3 antigen detection by ELISA in human serum(2007)